Proteon Therapeutics (PRTO) vs. Its Rivals Head-To-Head Survey

Proteon Therapeutics (NASDAQ: PRTO) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Proteon Therapeutics to similar companies based on the strength of its profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares Proteon Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Proteon Therapeutics $2.95 million -$28.52 million -0.83
Proteon Therapeutics Competitors $284.28 million $33.78 million 74.50

Proteon Therapeutics’ peers have higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Proteon Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A -105.58% -77.60%
Proteon Therapeutics Competitors -5,311.45% -218.34% -39.53%

Risk & Volatility

Proteon Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Proteon Therapeutics’ peers have a beta of 8.40, meaning that their average share price is 740% more volatile than the S&P 500.

Institutional and Insider Ownership

50.1% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 36.3% of Proteon Therapeutics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Proteon Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 7 1 0 2.13
Proteon Therapeutics Competitors 858 3204 11628 231 2.71

Proteon Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 79.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.38%. Given Proteon Therapeutics’ higher possible upside, analysts clearly believe Proteon Therapeutics is more favorable than its peers.

Summary

Proteon Therapeutics peers beat Proteon Therapeutics on 8 of the 12 factors compared.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply